Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease
Journal of Clinical Medicine · 24.01.2024 · 13 (3) · 669
DOI: 10.3390/jcm13030669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.01.2024. Verfasst von Cristina Suárez Ferrer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Unit, Digestive Medicine Service, Hospital Universitario La Paz, 28046 Madrid, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The rates of clinical and biochemical responses in Crohn’s disease (CD) patients treated with intravenous (IV) ustekinumab (UST) intensification are scarcely described.
Methods
Patients with diagnosis of CD who were under intensified IV ustekinumab treatment (130 mg every 4 weeks) were retrospectively included, evaluating the clinical and biochemical response 12 weeks after the change in treatment regimen (switch from SC to IV), as well as the serum levels of the drug.
Results
Twenty-seven patients, all of whom had transitioned to intensified intravenous ustekinumab treatment due to a secondary loss of response to the drug, were included in the retrospective analysis. At the baseline visit, prior to changing IV UST, differences in levels were observed between intensified and non-intensified patients (7216 vs. 2842 ng/mL, p = 0.00005). However, no significant differences were found between these two groups 12 weeks after IV intensification (7949 vs. 7937 ng/mL; p = 0.99). In patients with previous intensified UST SC, a decrease in fecal calprotectin was observed 12 weeks after starting IV intensification, going from a mean of 1463 ug/g to 751 ug/g, although the differences were not significant (p = 0.14).
Conclusion
In our experience, intensifying treatment with IV UST leads to clinical and biochemical improvements in CD patients with a secondary loss of response to SC maintenance with this drug, and an increase in drug levels was observed 12 weeks after IV UST intensification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Inflammatory Bowel Disease Unit, Digestive Medicine Service, Hospital Universitario La Paz, 28046 Madrid, Spain.
- IdiPAZ Study Group for Immune-Mediated Gastrointestinal Diseases, 28049 Madrid, Spain.
- Faculty de Medicina, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
ORCID-Profile: Cristina Suárez Ferrer, Joaquín Poza Cordón
Zitieren
APA
Suárez Ferrer, C., Arroyo Argüelles, J., Rueda García, J. L., García Ramírez, L., Martin Arranz, E., Sánchez Azofra, M., Poza Cordón, J., Noci Belda, J., & Martin-Arranz, M. D. (2024). Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease. Journal of Clinical Medicine, 13(3), 669. https://doi.org/10.3390/jcm13030669
Vancouver
Suárez Ferrer C, Arroyo Argüelles J, Rueda García JL, García Ramírez L, Martin Arranz E, Sánchez Azofra M, et al. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease. Journal of Clinical Medicine. 2024;13(3):669. doi:10.3390/jcm13030669
BibTeX
@article{SurezFerrer2024,
author = {Suárez Ferrer, Cristina and Arroyo Argüelles, José and Rueda García, Jose Luis and García Ramírez, Laura and Martin Arranz, Eduardo and Sánchez Azofra, María and Poza Cordón, Joaquín and Noci Belda, Jesús and Martin-Arranz, Maria Dolores},
title = {Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {3},
pages = {669},
doi = {10.3390/jcm13030669}
}
EUVIMED